Drug information of Gadopentetate dimeglumine

Gadopentetate dimeglumine

Drug group:

Gadopentetate dimeglumine (Magnevist) a complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs.

Mechanism of effect

Paramagnetic agent; exposure to external magnetic field in gadopentetate may induce a large magnetic field. The local magnetism may change proton density and spin characteristics, which it is then detected by the imaging device


Excretion: urine (90-100%)

Dialyzable: yes

Vd: 266 mL/kg; does not cross intact brain barrier

Half-life: 1.6 hr

Excretion: Urine (91%)


It has injectable solution 469.01mg/mL

MRI contrast agent dose 0.2 mL/kg IV bolus; not to exceed infusion rate of 10 mL/15 seconds

Dosing in patients > 286 pounds not studied

Side effects

Headache , nausea , vertigo


Atenolol , Propranolol , Metoprolol


Black Box Warnings

Risk for nephrogenic systemic fibrosis (NSF) with acute or chronic renal insufficiency (GFR <30 mL/min/1.73 m²), hepatorenal syndrome, or acute renal insufficiency resulting from perioperative liver transplant

NSF affects internal organs, skin, and muscle and can be fatal

Only use if essential and MRI cannot not provide appropriate diagnostic image

Screen for renal dysfunction, not to exceed recommended dosage, and allow for drug elimination before giving subsequent doses


Screen all patients for renal dysfunction

Thrombotic syndromes, anemia, hepatic/renal impairment, hemoglobinopathies (sickle cell anemia)

Risk for nephrogenic systemic fibrosis (NSF) in patients w/acute or chronic severe renal insufficiency, hepatorenal syndrome or in perioperative liver transplantation period (see Black Box Warnings)

Risk of hypotension

Site of injection may develop thrombosis

History of grand mal seizure

Safety of repeat doses not studied

Brain deposits

7/28/2015: FDA is investigating the risk of brain deposits following repeated use of gadolinium-based contrast agents (GBCAs) for MRI

Recent publications in the medical literature have reported that deposits of GBCAs remain in the brains of some patients who undergo ≥4 contrast MRI scans, long after the last administration

It is unknown whether these gadolinium deposits are harmful or can lead to adverse health effects

Early data in rat studies show that linear GBCAs are more prone to dissociation into free gadolinium and demonstrate greater brain deposition than macrocyclic GBCAs, which are less prone to dissociation

Points of recommendation

Tell all of your health care providers that you take this medicine. This includes your doctors, nurses, pharmacists, and dentists.

Very bad and sometimes deadly allergic reactions have rarely happened. Talk with your doctor.

Kidney failure has happened with gadopentetate dimeglumine in people who already had kidney problems. Talk with the doctor.

Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this medicine while you are pre gnant.

Some side effects that you need tell your doctor:

Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Signs of kidney problems like unable to pass urine, change in how much urine is passed, blood in the urine, or a big weight gain.

This medicine may cause tissue damage if the drug leaks from the vein. Tell your nurse if you have any redness, burning, pain, swelling, blisters, skin sores, or leaking of fluid where the drug is going into your body.

Pregnancy level


Related drugs

Gadodiamide , Gadavist , Dotarem

Ask a Pharmacist

User's questions
    No comments yet.